Difficulty: Medium
Average Score: 95%
Practice
Modest improvement in the memory of patients with alzheimer's disease may occur with drugs that increase transmission at which of the following receptors?
Correct answer
B
Rationale
In the context of lifespan pharmacology, understanding the effects of drugs on different receptor systems is crucial. In this question, the correct answer is B) Cholinergic.
Patients with Alzheimer's disease typically have decreased cholinergic transmission in the brain, leading to cognitive impairments such as memory loss. Drugs that increase transmission at cholinergic receptors can help improve memory and cognitive function in these patients. Cholinergic drugs like acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine) are commonly prescribed for Alzheimer's disease to enhance cholinergic neurotransmission and alleviate symptoms.
Now, let's discuss why the other options are incorrect:
A) Adrenergic: Drugs that target adrenergic receptors are not typically associated with memory improvement in Alzheimer's disease.
C) GABAergic: GABA is an inhibitory neurotransmitter, and drugs that enhance GABAergic transmission are not known to improve memory in Alzheimer's patients.
D) Dopaminergic: While dopamine plays a role in cognition and memory, drugs that increase dopaminergic transmission are not the primary pharmacological approach for treating memory deficits in Alzheimer's disease.
In an educational context, understanding the specific neurotransmitter systems involved in different neurological conditions like Alzheimer's disease is essential for pharmacology students and healthcare professionals. This knowledge helps in selecting appropriate pharmacological interventions to target the underlying mechanisms of cognitive impairments in patients.
Patients with Alzheimer's disease typically have decreased cholinergic transmission in the brain, leading to cognitive impairments such as memory loss. Drugs that increase transmission at cholinergic receptors can help improve memory and cognitive function in these patients. Cholinergic drugs like acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine) are commonly prescribed for Alzheimer's disease to enhance cholinergic neurotransmission and alleviate symptoms.
Now, let's discuss why the other options are incorrect:
A) Adrenergic: Drugs that target adrenergic receptors are not typically associated with memory improvement in Alzheimer's disease.
C) GABAergic: GABA is an inhibitory neurotransmitter, and drugs that enhance GABAergic transmission are not known to improve memory in Alzheimer's patients.
D) Dopaminergic: While dopamine plays a role in cognition and memory, drugs that increase dopaminergic transmission are not the primary pharmacological approach for treating memory deficits in Alzheimer's disease.
In an educational context, understanding the specific neurotransmitter systems involved in different neurological conditions like Alzheimer's disease is essential for pharmacology students and healthcare professionals. This knowledge helps in selecting appropriate pharmacological interventions to target the underlying mechanisms of cognitive impairments in patients.